Tag: msk

siRNA, Anti-Human LRRC41, LNA (SIRGT34852WQ-LNA)

For research use only. Not intended for any clinical use. Name * Phone * Email * Subject Project Description …

Continue Reading siRNA, Anti-Human LRRC41, LNA (SIRGT34852WQ-LNA)

Memorial Sloan Kettering Cancer Center hiring Bioinformatics Software Engineer III – Chan Lab in New York, NY

 The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative…

Continue Reading Memorial Sloan Kettering Cancer Center hiring Bioinformatics Software Engineer III – Chan Lab in New York, NY

Team Leader Bioinformatics – Ryvu Therapeutics, Krakow

Team Leader Bioinformatics – Ryvu Therapeutics, Krakow Team Leader Bioinformatics Ryvu Therapeutics Krakow, Poland As Bioinformatics Team Leader you will be responsible for development of this area within Data Science department which includes managing and growing the team, setting and executing short and long term plans, propagating collaboration with other…

Continue Reading Team Leader Bioinformatics – Ryvu Therapeutics, Krakow

qPCR Reagents Market is Anticipated to reach above USD 2.12 billion by 2030, grow at +8 % CAGR from 2023 to 2030

qPCR Reagents Market qPCR Reagents Market is expected to grow at 8 % CAGR from 2023 to 2030. It is expected to reach above USD 2.12 billion by 2030 from USD 1.23 billion in 2023. qPCR reagents are essential components used in the qPCR or RT-PCR process, allowing researchers to…

Continue Reading qPCR Reagents Market is Anticipated to reach above USD 2.12 billion by 2030, grow at +8 % CAGR from 2023 to 2030

Formononetin | FGFR2 inhibitor | Axon 4067

All All Products Enzymes Receptors Ion Channels Research Areas Oxidoreductases Transferases Lyases Isomerases Ligases Nuclear Receptors Ligand-gated ATP-Sensitive Angiogenesis Apoptosis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics Immunology Miscellaneous Pain & Inflammation Stem Cell Oxidases MAO Cys-loop, cationic Cis-Trans Isomerase CypA DNA Topoisomerase Synthetases…

Continue Reading Formononetin | FGFR2 inhibitor | Axon 4067

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

siRNA, Anti-Human ALAS1, 2′-F (SIRGT02138WQ-2F)

For research use only. Not intended for any clinical use. Name * Phone * Email * Subject Project Description …

Continue Reading siRNA, Anti-Human ALAS1, 2′-F (SIRGT02138WQ-2F)

Single Gene Disruption May Enhance CAR T Cell Therapy: Study

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient’s T cells so they recognize and attack cancer cells. These CAR (chimeric antigen receptor) T cells are then multiplied in a…

Continue Reading Single Gene Disruption May Enhance CAR T Cell Therapy: Study

Disrupting a Single Gene Could Improve CAR T Cell Immunotherapy, New Study Shows

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient’s T cells so they recognize and attack cancer cells. These CAR (chimeric antigen receptor) T cells are then multiplied in a…

Continue Reading Disrupting a Single Gene Could Improve CAR T Cell Immunotherapy, New Study Shows

How interactions between tumor genes and microenvironment influence treatment response in multiple myeloma

Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact…

Continue Reading How interactions between tumor genes and microenvironment influence treatment response in multiple myeloma

Characterization of the genomic alterations in poorly differentiated thyroid cancer

Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690. doi.org/10.1016/j.cell.2014.09.050 (2014). Sherman, S. I. Thyroid carcinoma. Lancet 361, 501–511. doi.org/10.1016/s0140-6736(03)12488-9 (2003). Article  PubMed  Google Scholar  Tong, J. et al. Poorly differentiated thyroid carcinoma: a clinician’s perspective. Eur. Thyroid J. 11, doi.org/10.1530/ETJ-22-0021 (2022). Asioli, S….

Continue Reading Characterization of the genomic alterations in poorly differentiated thyroid cancer

Bioinformatics jobs in New York

Broaden your search Refine your search Sign up for job alerts Get new jobs for this search by email Found 1 job for $200,000 or more Position URL to apply: apply.interfolio.com/132461   The Cecil H. and…

Continue Reading Bioinformatics jobs in New York

Memorial Sloan Kettering Cancer Center hiring Bioinformatics Software Engineer II in New York, New York, United States

$96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate…

Continue Reading Memorial Sloan Kettering Cancer Center hiring Bioinformatics Software Engineer II in New York, New York, United States

Actinium Pharma (ATNM) Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering’s CAR-T Cell Therapy

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT, Actinium’s…

Continue Reading Actinium Pharma (ATNM) Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering’s CAR-T Cell Therapy

Predicting tumour content of liquid biopsies from cell-free DNA | BMC Bioinformatics

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. Article  PubMed  Google Scholar  Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al….

Continue Reading Predicting tumour content of liquid biopsies from cell-free DNA | BMC Bioinformatics

Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

What You Should Know: Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the…

Continue Reading Mission Bio Announces and Launches Single-Cell Measurable Residual Disease (MRD) Assay –

Pancreatic Cancer Battle Boosted by $200M VC Firm

PRESS RELEASE Published September 19, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 USA News Group A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial Sloan…

Continue Reading Pancreatic Cancer Battle Boosted by $200M VC Firm

Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer

Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad’s minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. The partners will be…

Continue Reading Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer

Bioinformatics Software Engineer II – Chan Lab – New York

Pay Range $96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

Continue Reading Bioinformatics Software Engineer II – Chan Lab – New York

Rumble in the Genome: Unlocking the Secrets of the Tiny RNAs That Keep Self-Serving, Harmful Genes in Check

Developmental biologist Eric Lai, PhD, and his lab at Memorial Sloan Kettering Cancer Center (MSK) have been studying hotbeds of biological conflict. Only instead of battles between outside invaders and internal defenders, they’ve uncovered an evolutionary battle of the sexes fought using a group of recently emerged genes. This conflict…

Continue Reading Rumble in the Genome: Unlocking the Secrets of the Tiny RNAs That Keep Self-Serving, Harmful Genes in Check

Bioinformatician jobs in Marshfield, WI

Skip to main contentThe Muse LogoA logo with &quat;the muse&quat; in dark blue text. All Filters Company Filters Company IndustryCompany SizePerks and BenefitsDiversity & Inclusion View 29 Results Bioinformatician Posted on Data Scientist / Bioinformatician, Biologics R&D Posted on mRNA – Bioinformatician Scientist – All Gender Posted on Senior Crop…

Continue Reading Bioinformatician jobs in Marshfield, WI

Scientists Discover Secret Link Between Two Key Cancer Hallmarks

Research spearheaded by MSK unveiled a surprising connection between chromosomal instability and epigenetic changes, both of which are hallmarks of cancer — especially advanced, drug-resistant cancers. These defects work collectively, creating variations among individual cancer cells within the same tumor, thereby increasing their survival and resistance to treatment. The revelation…

Continue Reading Scientists Discover Secret Link Between Two Key Cancer Hallmarks

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response

SF3B1 MUT cells show selective sensitivity to PARP inhibitors To identify candidate therapeutic targets for cancers with SF3B1 hotspot mutations, we utilized the leukemia K562K700E (SF3B1K700E) and parental (SF3B1WT) isogenic cells1, to model one of the most prevalent SF3B1 hotspot mutations seen in patients8,19,20 (Fig. 1a,b and Supplementary Fig. 1a)….

Continue Reading SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response

New Progress Using Liquid Biopsies to Analyze cfDNA for Endometrial and Cervical Cancers

Liquid biopsies have the potential to revolutionize cancer diagnosis and treatment decisions. Unlike biopsies that require removing tumor tissue, these tests use a simple blood draw to assess the molecular characteristics of cancer. Liquid biopsies can be done repeatedly and quickly, offering researchers a less invasive way to detect cancer…

Continue Reading New Progress Using Liquid Biopsies to Analyze cfDNA for Endometrial and Cervical Cancers

Bioinformatics Software Engineer II – Memorial Sloan Kettering Cancer Center

Pay Range: $96,800.00-$154,900.00 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

Continue Reading Bioinformatics Software Engineer II – Memorial Sloan Kettering Cancer Center

Bioinformatics Software Engineer II in New York, NY for Memorial Sloan Kettering Cancer Center

Details Posted: 23-Jul-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages….

Continue Reading Bioinformatics Software Engineer II in New York, NY for Memorial Sloan Kettering Cancer Center

Kaggle is a practical study of Big Data. What is this platform and how does it work

Skip to content Prog.World Prog.World Toggle Menu Share this: Facebook Reddit Pinterest Telegram WhatsApp Skype Post navigation Previous Previous Parsing a small application with jokes NextContinue How ChatGPT User Data Leaks Are Framing Users Similar Posts Online meetup of the MSK VUE.JS developer community Python – Dict You can’t just…

Continue Reading Kaggle is a practical study of Big Data. What is this platform and how does it work

Dealing with failure of cBioPortal’s cBioDataPack() function to recognize a valid studyId?

Hi all, I attempted to download a list of multi assay experiments using cBioDataPack a moment ago. after cbio <- cBioPortal() studies <- getStudies(cbio, buildReport = TRUE) PedPanCanStudyIds<-studies[grepl(‘Ped’, studies$name, ignore.case=TRUE) & grepl(‘Pan’, studies$name, ignore.case=TRUE), ]$studyId I ran PedPanCanMaeList<-list(); setwd(oD) PedPanCanMaeList[[PedPanCanStudyIds[1]]]<-cBioDataPack(PedPanCanStudyIds[1]); saveRDS(PedPanCanMaeList[[ PedPanCanStudyIds[1] ]], file=paste0(‘./cBioPortal/’, PedPanCanStudyIds[1], ‘.Rds’) ) PedPanCanMaeList[[PedPanCanStudyIds[2]]]<-cBioDataPack(PedPanCanStudyIds[2]); saveRDS(PedPanCanMaeList[[ PedPanCanStudyIds[2]…

Continue Reading Dealing with failure of cBioPortal’s cBioDataPack() function to recognize a valid studyId?

Using Next-Generation Sequencing for personalized cancer vaccines

BioNTech, Moderna, and CureVac are the three leading companies working on cancer vaccines based on personalized neoantigens. Even though the average population will know of BioNTech and Moderna for their COVID-19 work, the original business model was heavily centered around cancer therapies, which is what we will cover here. BioNTech…

Continue Reading Using Next-Generation Sequencing for personalized cancer vaccines

Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Read the Full Video Transcript Sam Chang: Hello everyone, I’m Sam Chang. I’m a urologist at Vanderbilt University in Nashville, Tennessee and we’re quite fortunate to have a rising superstar in urologic oncology, Dr. Tim Clinton. Tim was a resident at UT Southwestern and finished his fellowship at Memorial Sloan…

Continue Reading Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

UPDATE 1-Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data

(Adds Moderna’s comments on potential to seek accelerated approval in paragraphs 2-3, Phase 3 confirmatory study in paragraph 8) By Julie Steenhuysen CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread…

Continue Reading UPDATE 1-Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data

Cancer vaccines poised to unlock ‘new treatment paradigm’ – Newspaper

CHICAGO: Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the deadliest skin cancer would spread by 65 per cent over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. The results, presented at the American Society of…

Continue Reading Cancer vaccines poised to unlock ‘new treatment paradigm’ – Newspaper

Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data

[1/2] Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc (MRNA.O) and Merck & Co (MRK.N) reduced the risk that the most deadly skin cancer would…

Continue Reading Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data

Cell-Free DNA Shows Promise as Cardiotoxicity Biomarker in HER2-Positive Breast Cancer Patients

NEW YORK — Cell-free DNA (cfDNA) derived from injured or dead cardiomyocytes is a promising biomarker to predict cancer therapy-related cardiac dysfunction (CTRCD) in HER2-positive breast cancer patients who undergo anthracycline chemotherapy, a new study has found. Previous studies have shown that anthracycline chemotherapy, which works by damaging cancer cell DNA, can…

Continue Reading Cell-Free DNA Shows Promise as Cardiotoxicity Biomarker in HER2-Positive Breast Cancer Patients

New York Hire Now – Memorial Sloan-Kettering Cancer Center Bioinformatics Software Engineer I

Pay Range $78,900.00-$126,200.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

Continue Reading New York Hire Now – Memorial Sloan-Kettering Cancer Center Bioinformatics Software Engineer I

MSK’s Sloan Kettering Institute celebrates 75

When the Sloan Kettering Institute opened its doors on Friday, April 16, 1948, an Associated Press wire story announced: “The world’s greatest cancer center opened here today.” And over the last seven and a half decades, institute researchers have made important contributions to the fundamental understanding of human biology, as well as…

Continue Reading MSK’s Sloan Kettering Institute celebrates 75

Gene Knockdown Market Booming at a CAGR of +20% by 2030 |Santa Cruz Biotechnology (US), OriGene (US), Sigma-Aldrich (US)

PRESS RELEASE Published May 5, 2023 New Jersey, N.J, May. 05, 2023 (Digital Journal) Gene knockdown is a technique used in molecular biology to decrease the expression of a gene of interest. This can be accomplished using RNA interference (RNAi), a technique that uses short strands of RNA to specifically…

Continue Reading Gene Knockdown Market Booming at a CAGR of +20% by 2030 |Santa Cruz Biotechnology (US), OriGene (US), Sigma-Aldrich (US)

MSK Discovery of ESR1 Gene Mutation Leads to Approval of Breast Cancer Drug Elacestrant

Earlier this year, the U.S. Food and Drug Administration (FDA) approved the drug elacestrant (Orserdu™) for certain people with advanced or metastatic breast cancer (stages 3 and 4). Elacestrant was effective in patients whose tumors were ER-positive, HER2-negative; had continued to grow after hormone therapy; and had a mutation (change)…

Continue Reading MSK Discovery of ESR1 Gene Mutation Leads to Approval of Breast Cancer Drug Elacestrant

African Ancestry Genetically Linked to Worse CRC Outcomes

ORLANDO, Florida — Non-Hispanic persons of African ancestry typically have worse clinical outcomes from colorectal cancer (CRC) than individuals of other heritages, a disparity attributed to many factors, including socioeconomic, environmental, and genetic influences, as well as less access to care. Results from a new genomic study provide greater clarity…

Continue Reading African Ancestry Genetically Linked to Worse CRC Outcomes

Study Explores Genomic Basis of Racial Disparities Among Patients With Colorectal Cancer

By Jo CavalloPosted: 4/18/2023 10:44:00 AM Last Updated: 4/18/2023 12:19:55 PM Black individuals are disproportionately affected by colorectal cancer. They have the highest rates of the disease of any racial or ethnic group in the United States, and are about 20% more likely to develop colorectal cancer and about 40%…

Continue Reading Study Explores Genomic Basis of Racial Disparities Among Patients With Colorectal Cancer

Colorectal cancer patients with African ancestry have fewer clinically actionable alterations than white patients: Study

Credit: CC0 Public Domain Genomic profiling of patients who were treated for colorectal cancer at a major U.S. cancer center showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry and were less likely to qualify for treatment with immunotherapy, according to data presented at…

Continue Reading Colorectal cancer patients with African ancestry have fewer clinically actionable alterations than white patients: Study

Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers

Background: FBXW7 is recognized as a critical tumor suppressor gene and a component of the ubiquitin-proteasome system, mediating the degradation of multiple oncogenic proteins, including c-MYC, Cyclin E, c-Jun, Notch, p53. Around 16% of colorectal cancer (CRC) patients carried FBXW7 somatic mutations, while a comprehensive characterization of FBXW7 somatic mutations…

Continue Reading Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers

Bioinformatics Software Engineer III, Data Scientist in New York, NY for Memorial Sloan Kettering Cancer Center

Details Posted: 12-Apr-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $116,800.00-$192,800.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery,…

Continue Reading Bioinformatics Software Engineer III, Data Scientist in New York, NY for Memorial Sloan Kettering Cancer Center

Bioinformatics Software Engineer III, Data Scientist in New York, NY for Memorial Sloan-Kettering Cancer Center

Details Posted: 12-Apr-23 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Pay Range $116,800.00-$192,800.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation…

Continue Reading Bioinformatics Software Engineer III, Data Scientist in New York, NY for Memorial Sloan-Kettering Cancer Center

Cell-Free DNA Sequencing Can Detect Clonal Hematopoiesis in Cancer Patients

NEW YORK – Researchers from the Novartis Institutes for BioMedical Research (NIBR) have developed a method to determine clonal hematopoiesis in cancer patients from cell-free DNA (cfDNA) alone, using a computational model that can discriminate between blood-derived mutations arising from clonal hematopoiesis of indeterminate potential (CHIP) and tumor-derived mutations. CfDNA sequencing is gaining…

Continue Reading Cell-Free DNA Sequencing Can Detect Clonal Hematopoiesis in Cancer Patients

Baptist Health is First in the State to Conduct Novel Liquid Biopsy in Brain Cancer Patient

March 22, 2023 – As part of an international clinical trial, Miami Cancer Institute and Miami Neuroscience Institute, part of Baptist Health South Florida, have conducted the first low-intensity focused ultrasound (LIFU) aided liquid biopsy in the state of Florida in a patient with glioblastoma, most aggressive form of brain cancer….

Continue Reading Baptist Health is First in the State to Conduct Novel Liquid Biopsy in Brain Cancer Patient

Cancer vaccine research may have reached ‘tipping point’

March 22, 2023 10 min read Source/Disclosures Published by: Disclosures: Disis reports being a stockholder/founder of EpiThany; grants from Aston Sci. and Bavarian Nordic during the conduct of the breast cancer vaccine study; serving as editor of JAMA Oncology outside the submitted work; and royalties for a…

Continue Reading Cancer vaccine research may have reached ‘tipping point’

Flare Therapeutics sees $123M oncology boost

Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has announced a $123 million Series B financing. The financing was co-led by GordonMD Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management,…

Continue Reading Flare Therapeutics sees $123M oncology boost

Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel

Brown JS O’Carrigan B Jackson SP Yap TA Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2017; 7: 20-37 Farmer H McCabe N Lord CJ Tutt AN Johnson DA Richardson TB Santarosa M Dillon KJ Hickson I Knights C Martin NM Jackson SP Smith GC Ashworth A Targeting…

Continue Reading Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel

Nirogacestat, a new desmoid tumor treatment,

A phase 3 clinical trial (research study) of a targeted therapy called nirogacestat has found that the drug significantly shrank desmoid tumors in 41% of patients. Desmoid tumors (also known as aggressive fibromatosis) are a rare type of soft tissue tumor, and MSK has a team of doctors who are dedicated…

Continue Reading Nirogacestat, a new desmoid tumor treatment,

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes –                   – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical…

Continue Reading SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial

CAR T cell therapy, often referred to as a “living drug,” has successfully treated blood cancers such as leukemia and lymphoma. The approach, which was pioneered at Memorial Sloan Kettering Cancer Center (MSK), involves equipping a person’s own immune cells (called T cells) with special receptors that can find cancer in…

Continue Reading Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi … | News

– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes –                    – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage…

Continue Reading SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi … | News

5 female-led biotech startups making waves

International Women’s Day takes place on March 8, which celebrates the achievements of women, and also shines a light on gender discrimination and the need to accelerate gender parity.  Although the percentage of women in the life sciences industry as a whole is almost equal to that of men, there…

Continue Reading 5 female-led biotech startups making waves

Actinium Pharma to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B By Investing.com

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase…

Continue Reading Actinium Pharma to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B By Investing.com

Bioinformatics Specialist in New York, NY for Memorial Sloan Kettering Cancer Center

Details Posted: 22-Feb-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $63,700.00-$98,700.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery,…

Continue Reading Bioinformatics Specialist in New York, NY for Memorial Sloan Kettering Cancer Center

Bioinformatics Specialist in New York, NY for Memorial Sloan-Kettering Cancer Center

Details Posted: 22-Jan-23 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Pay Range $63,700.00-$98,700.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation…

Continue Reading Bioinformatics Specialist in New York, NY for Memorial Sloan-Kettering Cancer Center

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Researchers develop new machete technique to slice into cancer genome and study copy number alterations — ScienceDaily

MACHETE is a new CRISPR-based technique developed by researchers at the Sloan Kettering Institute (SKI) to study large-scale genetic deletions efficiently in laboratory models. People are already calling it the Machete Paper. Still, lead authors Francisco “Pancho” Barriga and Kaloyan Tsanov of the Sloan Kettering Institute don’t want the name…

Continue Reading Researchers develop new machete technique to slice into cancer genome and study copy number alterations — ScienceDaily

Bioinformatics Software Engineer I – Genomics | Memorial Sloan Kettering Cancer Center

Nationwide, Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. We’re treating cancer, one patient at a time….

Continue Reading Bioinformatics Software Engineer I – Genomics | Memorial Sloan Kettering Cancer Center

Cell-Free DNA NGS Yields Low Detection in Metastatic ccRCC

Cell-free DNA-based next-general sequencing (NGS) yielded low detection rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to an analysis published in JCO Precision Oncology. Researchers performed NGS of tumor DNA and plasma DNA using the MSK-IMPACT platform in 110 patients with metastatic ccRCC. They explored detection…

Continue Reading Cell-Free DNA NGS Yields Low Detection in Metastatic ccRCC

Bioinformatics Software Engineer III in New York, NY for Memorial Sloan-Kettering Cancer Center

Details Posted: 05-Jul-22 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re…

Continue Reading Bioinformatics Software Engineer III in New York, NY for Memorial Sloan-Kettering Cancer Center

2022-60607 Bioinformatics Software Engineer I

Accessibility and Equal Opportunity If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are…

Continue Reading 2022-60607 Bioinformatics Software Engineer I

MSK Chief of the Lymphoma Service Gilles Sall

December 14, 2021, NEW YORK, NY – A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a…

Continue Reading MSK Chief of the Lymphoma Service Gilles Sall

Promising new treatment for patients with diffuse large B-cell lymphoma

Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin,…

Continue Reading Promising new treatment for patients with diffuse large B-cell lymphoma

BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors…

Continue Reading BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

Bioinformatics Software Engineer I – Memorial Sloan Kettering Cancer Center

At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes.  We’re treating cancer, one patient at a time. Join us and make a…

Continue Reading Bioinformatics Software Engineer I – Memorial Sloan Kettering Cancer Center

MSK Careers – Page Not Found

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…

Continue Reading MSK Careers – Page Not Found

2020-39864 Bioinformatics Software Engineer I

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…

Continue Reading 2020-39864 Bioinformatics Software Engineer I